Soluble ST2 (sST2) protein could be an additional non-invasive biomarker for monitoring patients with chronic thromboembolic pulmonary hypertension (CTEPH) undergoing interventional treatment with balloon pulmonary angioplasty (BPA), a study suggests. The study, “Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated…
News
Caring for a loved one with a rare disease, especially during these uncertain times, demands significant time, attention, patience, and dedication. To help meet that need, the National Organization for Rare Disorders (NORD)’s Rare Caregiver Respite Program may be a helpful resource. The program seeks to give a…
United Therapeutics is now among the leading sponsors of the Pulmonary Fibrosis Foundation (PFF) Registry, a research data resource for pulmonary fibrosis (PF) that is expanding to include pulmonary hypertension (PH) associated with PF, the foundation announced. Pulmonary hypertension that develops during the course of PF (characterized by scarring…
Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment for pulmonary arterial hypertension (PAH). “The acquisition of PHPM immediately expands Tenax’s pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first…
Nebulizer treatment with Tyvaso (inhaled treprostinil) can improve exercise capacity in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a study reports. The study, “Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease,” was published in The New England Journal of Medicine. ILD…
The HealthWell Foundation has opened a fund to help people with pulmonary hypertension (PH) in the U.S. who are on Medicare with covering their healthcare costs. The fund will offer awards of up to $10,000 over a one-year grant…
The prolargin protein may serve as a biomarker for pulmonary arterial hypertension (PAH), allowing for earlier diagnosis and differentiating among different types of pulmonary hypertension (PH), according to a recent study. The study, “Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension,” was…
The National Organization for Rare Disorders (NORD) is seeking individuals willing to share real-life experiences with rare diseases to speak at its upcoming virtual Living Rare, Living Stronger NORD Patient and Family Forum. The interactive, patient-focused forum will be held online June 26-27. The deadline to apply for…
A gene called DNMT3B was found for the first time to be a mediator of blood vessel wall growth, and has been implicated in the development of pulmonary hypertension (PH) in a rat study. This gene, which regulates inflammatory pathways…
Elevated blood levels of the kidney disease biomarker creatinine and the heart failure biomarker NT-proBNP were found to be independent predictors of mortality for older people with pulmonary arterial hypertension (PAH) who were born with congenital heart disease…
United Therapeutics is planning to ask the U.S. Food and Drug Administration (FDA) for an accelerated review of Tyvaso DPI, an investigational therapy-inhaler device treatment for two forms of pulmonary hypertension, in an approval request it expects to file by midyear. The request, in the form of a new drug…
Throughout 2020, Pulmonary Hypertension News brought daily coverage of groundbreaking research, treatment advancements, and clinical trial developments related to pulmonary hypertension (PH). As we anticipate bringing you more PH news this year, we take a look back…
